Targeting tumor necrosis factor alpha: New drugs used to modulate inflammatory diseases

Dermatologic Clinics

Volumn 19, Issue 4, 2001, Pages 617-635

  LaDuca, Jeffrey R ^a   Gaspari, Anthony A ^b  

^a UNIVERSITY OF ROCHESTER   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; INFLIXIMAB; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA;

AUTOIMMUNE DISEASE; CLINICAL TRIAL; CROHN DISEASE; CYTOKINE PRODUCTION; DRUG COST; DRUG INDICATION; DRUG INDUCED DISEASE; DRUG MARKETING; DRUG MECHANISM; DRUG STRUCTURE; DRUG TARGETING; HOST RESISTANCE; HUMAN; IMMUNOMODULATION; IMMUNOPHARMACOLOGY; INFLAMMATORY DISEASE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

EID: 0034760286     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8635(05)70304-1     Document Type: Article

References (177)

1. Cytokines
2. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptor
3. Tumor necrosis factor
4. Human tumor necrosis factor: Production, purification, and characterization
5. Immunological, clinical and molecular aspects of sarcoidosis
6. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes
7. TNF neutralization in MS: Results of a randomized, placebo-controlled multicenter study
8. Treatment of cutaneous lesions of systemic lupus erythematosus with thalidomide
9. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis
10. Phase II evaluation of thalidomide in patients with metastatic breast cancer
11. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis
12. Cellular immune effects of thalidomide in actinic prurigo
13. Tumor necrosis, cachexia, shock, and inflammation: A common mediator
14. Coordinate regulation of TNF biosynthesis at the levels of transcription and translation. Patterns of TNF expression in vivo
15. Tumor necrosis factor and lymphotoxin
16. Dual role of p75 tumor necrosis factor (TNF) receptor in TNF cytotoxicity
17. Thalidomide in patients with acquired immunodeficiency syndrome
18. Pathophysiologically relevant concentrations of tumor necrosis factor-a promote progressive left ventricular dysfunction and remodeling in rats
19. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor-α monoclonal antibody infliximab
20. Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis
21. Efficacy of thalidomide in the treatment of refractory ankylosing spondylitis
22. Tumor necrosis factor a-producing cells in the intestinal mucosa of children with inflammatory bowel disease
23. Prolonged activation of jun and collagenase genes by tumor necrosis factorα
24. Autoimmune skin rashes associated with etanercept for rheumatoid arthritis
25. An endotoxin induced serum factor that causes necrosis of tumors
26. Autoantigens targeted in systemic lupus erythematosus are clustered in two populations of surface structures on apoptotic keratinocytes
27. Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers
28. No thalidomide-related birth defects reported
29. Thalidomide neurotoxicity
30. Treatment of inoperable malignant tumors with the toxin of erysipelas and the Bacillus prodigiosus
31. Endogenous interleukin-1α is associated with skin irritation induced by tributylin
32. Thalidomide is an inhibitor of angiogenesis
33. New therapies for heart failure: Is thalidomide the answer?
34. Two human TNF receptors have similar extracellular, but distinct intracellular, domain sequences
35. Safety and efficacy of a soluble p75 tumor necrosis factor receptor (Enbrel, Etanercept) in patients with advanced heart failure
36. NF-kappa B activation by ultraviolet light not dependent on a nuclear signal
37. Longterm evolution of gut inflammation in patients with spondyloarthropathy
38. Endoscopic and histologic healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial
39. Thalidomide therapy for patients with refractory Crohn's disease: An open-label trial
40. Continuous low dose thalidomide: A phase II study in advanced melanoma, renal cell, ovarian and breast cancer
41. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor-α
42. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor-α (cA2) versus placebo in rheumatoid arthritis
43. Antibodies to a soluble form of tumor necrosis factor (TNF) receptor have TNF-like activity
44. Stereospecific determination, chiral inversion in vitro and pharmacokinetics in humans of the enantiomers of thalidomide
45. Enantiomers of thalidomide: Blood distribution and the influence of serum albumin on chiral inversion and hydrolysis
46. Elevated tumour necrosis factor-alpha (TNF-α biological activity in psoriatic skin lesions
47. Role of cytokines in rheumatoid arthritis
48. Tumor necrosis factor
49. Activity of thalidomide in AIDS-related Kaposi's sarcoma and correlation with HHV8 titer
50. Pharmacokinetics of thalidomide in an elderly prostate cancer population
51. Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas
52. IL- 10 inhibits cytokine production by activated macrophages
53. TNF and TGF-β: The opposite sides of the avenue?
54. What is the evidence that tumors are angiogenesis dependent?
55. Thalidomide neuropathy: A clinical electrophysiological, and histological follow-up study
56. Effectiveness of infliximab in the treatment of refractory perineal cutaneous Crohn's disease
57. Ovarian failure with thalidomide treatment in complex aphthosis: Comment on the concise communication by Ordi et al
58. Mast cells as a source of both preformed and immunologically inducible TNF-alpha/cachectin
59. Clinical and immunological improvement of a patient who received thalidomide treatment for refractory Mycobacterium avium complex infection
60. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor
61. Quantitative analysis of proinflammatory cytokines (IL-1beta, IL-6, TNF-alpha) in human skin wounds
62. Tumor necrosis factor alpha is pro-inflammatory in normal skin and modulates cutaneous adhesion molecule expression
63. Thalidomide in the treatment of the mucocutaneous lesions of the Behcet syndrome. A randomized, double blind, placebo-controlled trial
64. 2
65. The metabolic and immunologic effects of short-term thalidomide treatment of patients infected with human immunodeficiency virus
66. Thalidomide therapy of established collagen-induced arthritis (CIA) not accompanied by an evident Th 2 shift
67. Recalcitrant pyderma gangrenosum: Treatment with thalidomide
68. Treatment of AIDS-associated prurigo nodularis with thalidomide
69. Differential induction of cutaneous TNF-α and IL- 6 by topically applied chemicals
70. Role of the 75-kDa tumor necrosis factor receptor: Inhibition of early hematopoiesis
71. Thalidomide for the treatment of esophageal aphthous ulcers in patients with human immunodeficiency virus infection
72. Long term follow-up of patients treated with infliximab (anti-TNF-α antibody) in clinical trials
73. Chimeric anti-tumor necrosis factor-a monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy
74. Thalidomide in the treatment of refractory rheumatoid arthritis
75. Langerhans cells and chemical allergy
76. Biologic therapy for patients with rheumatoid arthritis
77. Construction and initial characterization of a mouse-human chimeric anti-TNT antibody
78. Thalidomide in the treatment of sixty cases of chronic discoid lupus erythematosus
79. Human keratinocytes as a source for tumor necrosis factor alpha: Evidence for synthesis and release upon stimulation with endotoxin or ultraviolet light
80. The pharmacokinetics of etanercept in healthy volunteers
81. Antigenicity of murine skin tumors induced by ultraviolet light
82. cis-Urocanic acid suppression of contact hypersensitivity induction is mediated via tumor necrosis factor-a
83. Thalidomide: An old drug for the new millennium
84. Elevated levels of circulating cachectin/tumor necrosis factor in patient with acquired immunodeficiency syndrome
85. Activated Langerhans cells release tumor necrosis factor
86. Disfiguring cutaneous manifestations of sarcoidosis treated with thalidomide: A case report
87. Die thalidomid-embryopathie
88. Infliximab and methotrexate in the treatment of rheumatoid arthritis
89. Etanercept in children with polyarticular juvenile rheumatoid arthritis
90. Thalidomide inhibits the replication of human immunodeficiency virus type 1
91. Etanercept in the treatment of psoriatic arthritis and psoriasis: A randomized trial
92. Therapeutic efficacy of multiple intervenous infusions of antitumor necrosis factor-a monoclonal antibody combined with low dose weekly methotrexate in rheumatoid arthritis
93. Infliximab (chimeric anti-tumour necrosis factor-a monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A randomised phase III trial
94. Ileocolonoscopic findings in seronegative spondyloarthropathies
95. Course of gut inflammation in spondylarthropathies and therapeutic consequences
96. The evolution of spondyloarthropathies in relation to gut histology. I. Clinical aspects
97. Protection against a lethal dose of endotoxin by an inhibitor of tumour necrosis factor processing
98. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists
99. Does administration of infliximab increase susceptibility to listeriosis?
100. Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation
101. Optimal dose of TNF receptor p75 Fc fusion protein (TNFR:Fc, Enbrel)
102. Treatment of rheumatoid arthritis with recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein
103. Longterm safety and efficacy of TNF receptor (p75) Fc fusion protein (TNFR:Fc, Enbrel) in DMARD refractory rheumatoid arthritis (RA)
104. Etanercept therapy for rheumatoid arthritis
105. Endocytic pathway of recombinant murine tumor necrosis factor in L 929 cells
106. Etanercept-associated injection site reactions
107. Molecular mechanisms involved in the migration of epidermal dendritic cells in the skin. Symposium Proceedings
108. Soluble forms of tumor necrosis factor receptors (TNF-Rs). The cDNA for the type I TNF-R, cloned using amino acid sequence data of its soluble form, encodes both the cell surface and a soluble form of the receptor
109. Treatment with antitumor necrosis factor alpha (TNF-alpha) monoclonal antibody dramatically decreases the clinical activity of psoriasis lesions
110. The effect of thalidomide and two analogs on collagen induced arthritis
111. Thalidomide analogue CC 1069 inhibits development of rat adjuvant arthritis
112. Thalidomide induces amenorrhea in patients with lupus disease
113. Thalidomide in the treatment of cutaneous lupus refractory to conventional therapy
114. Characterization of a recombinant extracellular domain of the type 1 tumor necrosis factor receptor: Evidence for tumor necrosis factor-α-induced receptor aggregation
115. Effects of recombinant tumor necrosis factor on proliferation and differentiation of leukemic and normal hematopoietic cells in vitro. Relationship to cell surface receptor
116. A nonsecretable cell surface mutant of tumor necrosis factor (TNF) kills by cell-to-cell contact
117. Tumor necrosis factor/cachetin is an effector of skin and gut lesions of acute phase of graft-vs-host disease
118. Tumor necrosis factor is a critical mediator in hapten-induced irritant and contact hypersensitivity reactions
119. Single dose pharmacokinetics of thalidomide in human immunodeficiency virus-infected patients
120. Human neutrophil elastase releases a ligand-binding fragment from the 75-kDa tumor necrosis factor (TNF) receptor. Comparison with the proteolytic activity responsible for shedding of TNF receptors from stimulated neutrophils
121. Infliximab for the treatment of fistulas in patients with Crohn's disease
122. Life-threatening toxic epidermal necrolysis with thalidomide therapy for myeloma
123. Mucosal inflammatory cytokine production by intestinal biopsies in patients with ulcerative colitis and Crohn's disease
124. Effects of thalidomide on HIV-associated wasting syndrome: A randomized, double-blind, placebo-controlled clinical trail
125. Mechanisms of angiogenesis
126. The interrelationship of tumor necrosis factor, glutathione, and AIDS
127. TRAF2-mediated activation of NFκB by TNF receptor 2 and CD40
128. Cutaneous sarcoidosis successfully treated with low doses of thalidomide
129. Patients receiving etanercept may develop antibodies that interfere with monoclonal antibody laboratory assays
130. Induction of vascular endothelial growth factor by tumor necrosis factor a in human glioma cells
131. Thalidomide selectivity inhibits tumor necrosis factor alpha production by stimulated human monocytes
132. Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety
133. Serum levels of tumour necrosis factor alpha and interleukin- 1b during leprosy reactional states
134. The metabolism of thalidomide: The fate of thalidomide and some of its hydrolysis products in various species
135. Ultraviolet-B-induced apoptosis of keratinocytes: Evidence for partial involvement of tumor necrosis factor-a in the formation of sunburn cells
136. Natural inhibitors of TNF
137. Faecal tumor necrosis factor-alpha in HIV-related diarrhoea
138. The treatment of microsporidial diarrhoea with thalidomide
139. Thalidomide: A novel therapy for microsporidiosis
140. Chemical treatment of tumors. V.Isolation of the hemorrhage producing fraction from Serratia marcescens culture filtrate
141. The treatment of lepra reactions in lepromatous leprosy: Fifteen years' experience with thalidomide
142. Thalidomide in the treatment of lepra reactions
143. Cloning and expression in Escherichia coli of the gene for human tumour necrosis factor
144. Antitumor activity of thalidomide in refractory multiple myeloma
145. The active form of tumor necrosis factor is a trimer
146. TNF-a and response of treatment-resistant adult-onset Still's disease to thalidomide
147. Neural influences on induction of contact hypersensitivity
148. Recombinant human tumor necrosis factor-: Effects on proliferation of normal and transformed cells in vitro
149. A short term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA 2 Study Group
150. Ligand passing: The 75-kDa tumor necrosis factor (TNF) receptor recruits TNF for signaling by the 55-kDa TNF receptor
151. The two different receptors for tumor necrosis factor mediate distinct cellular responses
152. Increased production of tumor necrosis factor by peripheral blood leukocytes in patients with recurrent oral aphthous ulcerations
153. Identification of a 60-kDa tumor necrosis factor (TNF) receptor as the major signal transducing component in TNF responses
154. Successful treatment of adult's Langerhans cell histiocytosis with thalidomide. Report of two cases and literature review
155. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor-α (infliximab) in spondyloarthropathy: An open pilot study
156. Tumour necrosis factor and Crohn's disease
157. Functional characterization of the human tumor necrosis factor receptor p75 in a transfected rat/mouse T cell hybridoma
158. Treatment of Crohn's disease with anti-tumor necrosis factor chimeric monoclonal antibody (cA2)
159. An open-label pilot study of low-dose thalidomide in chronically active, steroid-dependent Crohn's disease
160. Fibroblast growth enhancing activity of tumor necrosis factor and its relationship to other polypeptide growth factors
161. Afelimomab
162. Molecular cloning of the complementary DNA for human tumor necrosis factor
163. Depressed Langerhans cell migration and reduced contact hypersensitivity response in mouse lacking TNF receptor p 75
164. Effects of whole body UVB irradiation on cytokine production bt peripheral blood mononuclear cells from stage I melanoma patients
165. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate
166. Longterm and phase III treatment of DMARD failing rheumatoid arthritis patients with TNF receptor p75 Fc fusion protein (TNF:Fc, Enbrel)
167. Thalidomide's chirality
168. Keratinocyte-derived chemotactic cytokines: Expressional modulation by nitric oxide in vitro and during cutaneous wound repair in vivo
169. Randomised comparison of thalidomide versus placebo in toxic epidermal necrolysis
170. Development of polyneuropathy during thalidomide therapy
171. Sunburn and p 53 in the onset of skin cancer
172. Enhancement of cAMP levels and of protein kinase activity by tumor necrosis factor and interleukin 1 in human fibroblasts: Role in induction of interleukin 6
173. TNF receptor p 55 plays a pivotal role in murine keratinocyte apoptosis induced by ultraviolet B irradiation